The FDA has agreed to review an application from Roche that seeks approval in the U.S. of obinutuzumab as a treatment for ...
Conduit Pharmaceuticals (CDT) provides an R&D update on the development progress of pipeline assets AZD1656, AZD5658, and AZD5904. The ...
Conduit Pharmaceuticals advances its pipeline with key progress in preclinical lupus studies for AZD5658, Phase IIa trial design for AZD1656, formulation optimization, and IP expansion, positioning ...
Perimenopause is often associated with hot flashes and mood swings, but did you know it can also impact inflammation, immune function, and heart health? Dr. Shilpa Sayana, ...
Mar. 12, 2025 — Lupus is an autoimmune disease where the body's immune system attacks its own tissues and organs, causing inflammation and damaging organs. A new study has now shown that the ...
Q4 2024 Earnings Call Transcript March 11, 2025 Exagen Inc. beats earnings expectations. Reported EPS is $-0.2, expectations ...
Greetings and welcome to Exagen Inc fourth quarter 2024 earnings conference call. (Operator Instructions) As a reminder, this conference is being recorded. It is now my pleasure to introduce your host ...
Artiva Biotherapeutics' CEO Fred Aslan, MD, discusses the concept of an immune reset and what the company is tracking in ...
New research reveals disturbing nightmares and hallucinations may serve as early warning signs of lupus, potentially helping patients receive treatment sooner.
Three local genetic correlation (LGC) genomic prediction methods are proposed to incorporate LGCs into multi-trait genomic prediction and could universally improve prediction accuracy compared to ...
Despite advancements in the management of systemic lupus erythematosus (SLE), patients experience poor health-related quality of life (hrQoL) and premature death due to disease severity and treatment ...
Lupus nephritis is a serious complication of lupus that is caused by inflammation of the kidneys. It affects up to 60% of people with lupus and usually occurs within 5 years of diagnosis. If left ...